AN2 Therapeutics (ANTX) Share-based Compensation (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Share-based Compensation data on file, last reported at $1.5 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.5 million, down 28.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.7 million (down 29.26% YoY), and the FY2025 annual result was $6.2 million, down 25.09% from the prior year.
• Share-based Compensation advanced to $1.5 million in Q1 2026 per ANTX's latest filing, from $1.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $2.4 million in Q1 2024 and troughed at $449000.0 in Q1 2022.
• A 5-year average of $1.7 million and a median of $1.9 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 5512.5% in 2022, then plunged 57.89% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $1.5 million in 2022, then soared by 51.63% to $2.2 million in 2023, then fell by 20.25% to $1.8 million in 2024, then declined by 21.35% to $1.4 million in 2025, then rose by 4.29% to $1.5 million in 2026.
• Business Quant data shows ANTX's Share-based Compensation at $1.5 million in Q1 2026, $1.4 million in Q4 2025, and $801000.0 in Q3 2025.